183 related articles for article (PubMed ID: 33664457)
1. Prostate cryoablation combined with androgen deprivation therapy for newly diagnosed metastatic prostate cancer: a propensity score-based study.
Wang N; Ye Y; Deng M; Zhao D; Jiang L; Chen D; Wu Z; Wang Y; Li Z; Yang Z; Li J; Zhou F; Li Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):837-844. PubMed ID: 33664457
[TBL] [Abstract][Full Text] [Related]
2. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
[TBL] [Abstract][Full Text] [Related]
3. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
[No Abstract] [Full Text] [Related]
4. Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis.
Sheng M; Guo S; Liu C
World J Surg Oncol; 2021 Dec; 19(1):345. PubMed ID: 34903228
[TBL] [Abstract][Full Text] [Related]
5. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
[TBL] [Abstract][Full Text] [Related]
9. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
12. Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
Onozawa M; Akaza H; Hinotsu S; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Tsukamoto T
Cancer Med; 2018 Oct; 7(10):4893-4902. PubMed ID: 30151999
[TBL] [Abstract][Full Text] [Related]
13. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial.
Boevé L; Hulshof MCCM; Verhagen PCMS; Twisk JWR; Witjes WPJ; de Vries P; van Moorselaar RJA; van Andel G; Vis AN
Eur Urol; 2021 Feb; 79(2):188-197. PubMed ID: 32978014
[TBL] [Abstract][Full Text] [Related]
15. Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
Ginsburg KB; Elshafei A; Yu C; Jones JS; Cher ML
Prostate; 2017 Oct; 77(14):1446-1450. PubMed ID: 28856702
[TBL] [Abstract][Full Text] [Related]
16. The biochemical efficacy of primary cryoablation combined with prolonged total androgen suppression compared with radiotherapy on high-risk prostate cancer: a 3-year pilot study.
Ko YH; Kang SH; Park YJ; Park HS; Moon du G; Lee JG; Yoon DK; Kim JJ; Cheon J
Asian J Androl; 2010 Nov; 12(6):827-34. PubMed ID: 20711215
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant androgen-deprivation therapy following prostate total cryoablation in high-risk localized prostate cancer patients - Open-labeled randomized clinical trial.
Chen CH; Pu YS
Cryobiology; 2018 Jun; 82():88-92. PubMed ID: 29626465
[TBL] [Abstract][Full Text] [Related]
18. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
